Professor Sa Kyung-ha (Korea University College of Medicine), Professor Park Cheol-ki (Seoul National University Hospital), Professor Nam Do-hyeon (Samsung Seoul Hospital) and Professor Park Jong-bae (Director of Cancer Protein Genome Business Unit at the National Cancer Center)
[팜뉴스=김태일 기자] For the first time in the world, the results of research have been published that identified the evolutionary process of brain tumor recurrence through the analysis of the glioblastoma tumor protein genome and suggested a new treatment plan.
Professor Sa Kyung-ha’s research team at the Department of Medical Information of Korea University College of Medicine and Professor Park Jong-bae’s research team at the National Cancer Center revealed the evolutionary process of brain tumor recurrence through the genome analysis of the tumor protein of glioblastoma, one of the malignant brain tumors and devised a new treatment method.
Glioblastoma is one of the malignant brain tumors with limited treatment options, has several genetic mutations and is able to organically connect with brain neurons. Furthermore, the rate of recurrence after initial treatment is very high and it is known that most recurrent tumors are highly resistant to radiation and chemotherapy.
Through genome analysis of primary and recurrent malignant brain tumor glioblastoma tumor protein, the evolution process of relapse after standard anticancer treatment was identified, and the discovery of a diagnostic biomarker for WNTPCP and the possibility of a new target for the BRAF proteome.
The research team systematically followed the evolution of tumor cells after treatment by analyzing the genome, transcription and proteome of primary and recurrent tumors from 123 glioblastoma patients. Consequently, cancer relapsed after treatment acquired neuronal characteristics through activation of the WNT/PCP signaling pathway and the BRAF proteome. Furthermore, it has been verified through patient-derived cells and animal models that the formation of synapses with normal neurons existing in the tumor microenvironment is closely related to treatment resistance of recurrent cancer.
Furthermore, it was found that when vemurafenib, a targeted therapy with BRAF inhibition effect, was administered together with Temodal, a standard anticancer drug, the neuronal characteristics of recurrent tumor cells were suppressed and their invasion ability was inhibited. , and has been confirmed in animal models. that the survival period has increased significantly. Through this, we were able to demonstrate BRAF proteome inhibition as a novel target for recurrent glioblastoma and suggest a new direction for targeted therapy targeting this.
Professor Sa Kyung-ha said: “There were limitations in identifying patterns of tumor evolution through existing fragmentary genome analysis alone, but the results of this study have significant implications as they may suggest new treatment possibilities through multidimensional data analysis”.
Professor Jongbae Park said: “Through the integration of genome, proteome and clinical data, we have identified for the first time in the world that the formation of a network between nerve cells and brain tumor cells induces brain tumor recurrence.” .
This study was conducted with the support of the National Cancer Center Cancer Protein Genome Research Project and Cancer Cell, a world-renowned international academic journal,
#Professor #Kyungha #Korea #University #Medical #School #Professor #Park #Jongbae #National #Cancer #Center #raise #possibility #personalized #treatment #malignant #brain #tumors
.jpg?fit=300%2C300&ssl=1)
